Clinical Trials Logo

Colorectal Cancer Stage II clinical trials

View clinical trials related to Colorectal Cancer Stage II.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT06271980 Completed - Colorectal Cancer Clinical Trials

Early-Onset Colorectal Cancer Recurrence

ENCORE
Start date: April 15, 2023
Phase:
Study type: Observational

Survivors of early-onset colorectal cancer (diagnosed before age 50) may experience colorectal cancer recurrence several years after curative-intent treatments, but clinical guidelines provide unclear guidance on endoscopic surveillance. This study aims to predict recurrence-free survival and overall survival, in survivors of early-onset colorectal cancer, using a tumor-based molecular assay based on microRNA (ribonucleic acid)

NCT ID: NCT01853813 Completed - Clinical trials for Colorectal Cancer Stage II

First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer

CENTRAL
Start date: May 2013
Phase: Phase 2
Study type: Interventional

Bevacizumab in combination with chemotherapy represents a standard of care for first-line treatment in patients with advanced colorectal cancer. Molecular predictive factors for bevacizumab efficacy have not yet been identified therefore selection of patients more likely to benefit from such a treatment approach is not possible. Retrospective analyses suggested that LDH serum levels may influence the clinical activity of anti-angiogenetic drugs. Primary aim of our clinical trial will be to prospectively ascertain whether bevacizumab in combination with chemotherapy has an improved clinical activity in patients with high LDH serum levels compared to patients with normal LDH serum levels

NCT ID: NCT01570452 Completed - Clinical trials for Colorectal Cancer Stage IV

Matrilysin Expression in Different Stages of Colorectal Tumors

MMP7
Start date: September 2005
Phase: N/A
Study type: Observational

Matrix metalloproteinases (MMPs) have been shown to be involved in cancer biology. Significant expression of MMP-7 (matrilysin) in colorectal cancer is mainly associated with metastatic disease even though it is expressed in most tumor states. Our purpose is to analyse MMP-7 in bowel and lymph nodes of different tumor stages and to evaluate its expression as a potential biomarker of cancer disease in patients surgically treated for benign and malignant colorectal tumors. Tumoral tissue, lymph nodes and serum samples from recruited Patients plus serum samples from healthy volunteers are analysed for matrilysin expression by histology, immunohistochemistry, ELISA and Western blotting. If Matrilysin increases with increasing dysplasia and cancer disease stage in tumor tissue as well as in the regional lymph nodes it might be used as a complement in investigating suspected locally advanced cancer.